CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Appreciate the incidence of CEACAM5 overexpression in patients with non-small cell lung cancer (NSCLC), and develop an understanding of the rationale for therapeutically targeting this cell surface protein for metastatic disease.
  • Understand the structural components and mechanism of action of novel antibody-drug conjugates (ADCs) directed at CEACAM5.
  • Evaluate available efficacy and safety findings with CEACAM5-directed ADCs for metastatic NSCLC and assess the potential placement of this form of therapy in the current treatment algorithm.
  • Recognize the spectrum, frequency, severity and optimal management of toxicities associated with novel CEACAM5-directed ADCs under development in order to prepare for their safe and effective use.
  • Recall the design of ongoing clinical trials evaluating novel CEACAM5-directed ADCs for metastatic NSCLC, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.5 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Program: ResearchToPractice.com/OncologyTodayCEACAM5NSCLC23 and evaluation ResearchToPractice.com/OncologyTodayCEACAM5NSCLC23/CME.
  
  Video Program: ResearchToPractice.com/OncologyTodayCEACAM5NSCLC23/Video and evaluation ResearchToPractice.com/OncologyTodayCEACAM5NSCLC23/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Melissa Johnson, MD
  Director, Lung Cancer Research Program
  Sarah Cannon Research Institute
  Associate Director of Drug Development for the Drug Development
  Unit in Nashville
  SCRI Oncology Partners
  Nashville, Tennessee
  
  Consulting Agreements (All Payments Made to Institution): AbbVie Inc, Alentis Therapeutics AG, Amgen Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gilead Sciences Inc, Gritstone bio, GSK, Hookipa Pharma Inc, Immunocore, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Mirati Therapeutics Inc, Molecular Axiom, Normunity, Novartis, Novocure Inc, Pfizer Inc, Pyramid Biosciences, Revolution Medicines, Sanofi, Seagen Inc, Synthekine, Takeda Pharmaceuticals USA Inc, VBL Therapeutics; Contracted Research (All Payments Made to Institution): AbbVie Inc, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrivent BioPharma, Artios Pharma Limited, AstraZeneca Pharmaceuticals LP, Atreca, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BerGenBio ASA, BioAtla, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Centessa Pharmaceuticals, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Dynavax Technologies, Elicio Therapeutics, EMD Serono Inc, EQRx, Erasca, Exelixis Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gritstone bio, GSK, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences Inc, Immunocore, Immunitas Therapeutics, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Kadmon, Kartos Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, Merck, Merus BV, Mirati Therapeutics Inc, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics AG, Nuvalent, OncoMed Pharmaceuticals Inc, Palleon Pharmaceuticals, Pfizer Inc, PMV Pharma, Rain Oncology, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, SiliconTherapeutics, Stemcentrx, Syndax Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TarvedaTherapeutics, TCR² Therapeutics, Tempest Therapeutics, Tizona Therapeutics Inc, Tmunity Therapeutics, Turning Point Therapeutics Inc, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics Inc; Nonrelevant Financial Relationships (All Payments Made to Institution): City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University of Michigan.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Sanofi.
  
  Release date: March 2024
  Expiration date: March 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.